TEV Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TEV Stock 12 Month Forecast
Average Price Target
€39.05
▲(25.15% Upside)
| Highest Price Target€43.71 | Average Price Target€39.05 | Lowest Price Target€34.97 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
€37.59
Buy
20.48%
Upside
Reiterated
09/23/26
Leerink Partners
€39.34
Buy
26.09%
Upside
Initiated
09/09/26
UBS
€36.72→€41.96
Buy
34.49%
Upside
Reiterated
09/04/26
Scotiabank
€34.97
Buy
12.08%
Upside
Reiterated
09/03/26
Jefferies
€34.97
Buy
12.08%
Upside
Reiterated
09/03/26
Goldman Sachs
€43.71
Buy
40.10%
Upside
Reiterated
09/02/26
Evercore ISI
―
Buy
―
Reiterated
09/02/26
Piper Sandler
€38.47
Buy
23.29%
Upside
Reiterated
08/27/26
Barclays
€34.97→€36.72
Buy
17.68%
Upside
Reiterated
08/12/26
J.P. Morgan
―
Buy
―
Reiterated
06/15/26
Truist Financial
€36.72→€39.34
Buy
26.09%
Upside
Assigned
04/30/26
Guggenheim
―
Hold
―
Reiterated
11/18/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
€37.59
Buy
20.48%
Upside
Reiterated
09/23/26
Leerink Partners
€39.34
Buy
26.09%
Upside
Initiated
09/09/26
UBS
€36.72→€41.96
Buy
34.49%
Upside
Reiterated
09/04/26
Scotiabank
€34.97
Buy
12.08%
Upside
Reiterated
09/03/26
Jefferies
€34.97
Buy
12.08%
Upside
Reiterated
09/03/26
Goldman Sachs
€43.71
Buy
40.10%
Upside
Reiterated
09/02/26
Evercore ISI
―
Buy
―
Reiterated
09/02/26
Piper Sandler
€38.47
Buy
23.29%
Upside
Reiterated
08/27/26
Barclays
€34.97→€36.72
Buy
17.68%
Upside
Reiterated
08/12/26
J.P. Morgan
―
Buy
―
Reiterated
06/15/26
Truist Financial
€36.72→€39.34
Buy
26.09%
Upside
Assigned
04/30/26
Guggenheim
―
Hold
―
Reiterated
11/18/25
Best Analysts Covering Teva Pharmaceutical
3 Months
Success Rate
19/25 ratings generated profit
Average Return
+8.33%
Copying Ashwani Verma's trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +8.33% per trade.
1 Year
Success Rate
30/31 ratings generated profit
Average Return
+53.21%
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 96.77% of your transactions generating a profit, with an average return of +53.21% per trade.
2 Years
Success Rate
25/25 ratings generated profit
Average Return
+80.61%
Copying Ashwani Verma's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +80.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TEV Analyst Recommendation Trends
Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
20
20
19
22
24
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
20
19
22
24
Each month's total comprises the sum of three months' worth of ratings.
TEV Financial Forecast
TEV Stock Forecast FAQ
What is DE:TEV’s average 12-month price target, according to analysts?
Based on analyst ratings, Teva Pharmaceutical’s 12-month average price target is 39.05.
What is DE:TEV’s upside potential, based on the analysts’ average price target?
Teva Pharmaceutical has 25.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Teva Pharmaceutical a Buy, Sell or Hold?
Teva Pharmaceutical has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Teva Pharmaceutical’s share price target?
The average share price target for Teva Pharmaceutical is 39.05. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €43.71 ,and the lowest forecast is €34.97. The average share price target represents 25.15% Increase from the current price of €31.2.
The highest analyst share price target is €43.71 ,and the lowest forecast is €34.97. The average share price target represents 25.15% Increase from the current price of €31.2.
What do analysts say about Teva Pharmaceutical?
Teva Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of Teva Pharmaceutical?
To buy shares of DE:TEV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.